Drugs List Flashcards
Welcome to my drugs list deck. They should contain the MOA + usage & side effects that we need to know for every drug on the list. Some cards have ways to remember the drugs/picture prompts... also if there are any mistakes/any could be refined or made better please let me know and ill edit!
Antacids
- Aluminium Hydroxide and Magnesium Hydroxide - Maalox
- Calcium Carbonate and Magnesium Carbonate - Rennie
Gastric Acid Neutralisation
Uses: Reflux oesophagitis - OTC & prescribed
Antacids + Alginates
- Sodium Alginate with Sodium Bicarbonate, Calcium Carbonate (Gaviscon)
Anionic polysaccharides - form a viscous gel raft upon binding with water, this floats to the top of the stomach reducing symptoms. Also contains antacid to neutralise excess acid
Uses: Reflux oesophagitis - OTC + prescribed
H2 Receptor Antagonists
- Cimetidine
- Ranitidine
Competitively inhibits gastric H2 receptors to decrease acid secretion.
OTC
Cimetidine inhibits many cytochrome P450 enzymes
Proton Pump Inhibitors
- Omeprazole
- Lansoprazole
Blockade of parietal cell proton transporters:
Irreversibly inhibits H+/K+-ATPase pump, terminal step in acid secretion pathway. Decreases basal and stimulated acid production.
Very specific - inative at neutral pH thus accumulate in secretory canaliculi or parietal cells and are activated in acidic environment.
Prescribed drug of choice for reflux oesophagitiss.
More effective than H2 antagonists.
Bulk Laxatives
- Methylcellulose
- Isphagula Husk
Polysaccharide polymers not broken down by normal digestion so retain water in the GI lumen, softening and increasing bulk load and promoting increased motility.
Act over 1-3 days.
First line for constipation & IBS
Stimulant Purgatives (2)
- Bisacodyl
Stimulates rectal mucosa resulting in massmovements - defaecation in 15-30 mins
- Senna
Passes unchanges into colon where bacterial action causes direct effect on myenteric plexus to increase intestinal motility
Chronic use (>3/week for >year) can cause cathartic colon (laxative dependency + req. higher doses) can lead to serious consequences
Faecal Softeners
- Docusate
- Arachis oil
Anionic surfactants. Lower surface tension allowing water or fats to enter the stool, softening faeces. Stimulates water & electrolyte secretion into the intestinal lumen
Used for constipation and fissures/piles
Osmotic Laxatives (3)
- Saline purgatives - Magnesium sulphate, Magnesium Hydroxide -
Uses: Bowel prep before procedure. Potent, rapid action (1-2hrs)
- Macrogol Uses: Faecal impaction in children, LT management of chronic constipation
Poorly absorbed solutes that maintain increased fluid volume in GI tract by osmosis, accelerating small intestine transit - large fluid volume in colon leads to distension and purgation.
- Lactulose
Semi-synthetic disaccharide converted to poorly absorbed monocaccharides by colonic bacteria - Fermentation ields acetic acid which acts as an osmotic laxative
Acts 1-3 days
SEs: Abdo cramp, gas, flatulence
Oral Rehydration Therapy
- Isotonic/hypotonic solution of glucose and NaCl
Exploits ability of glucose to enhance absorption of Na+ and so water.
Opioid Anti-Motility Agents
- Codeine
- Loperamide
Agonist on u-opioid receptors in the myenteric plexus. Increases tone and rhythmic contractions of the colon, but diminishes propulsive activity. Pyloric, illocaecal and anal sphincters are contracted
SEs: Chronic use = constipation. Abdo cramps, dizziness
Uses: Acute uncomplicated diarrhoea in adults
Carbonic Anhydrase Inhibitor
- Acetazolomide
Inhibits carbonic anhydrase in PCT to stop the reapsorption of Na+ so increasing the volume of urine (osmotic balance). Weak diuretic action as only a small amount of sodium is reabsorbed this way
Also prevents H+ secretion (and HCO3- reabsorption) so can lead to metabolic acidosis
Uses: Reduce intraocular pressure in glaucoma (aqueous humour prod. req. HCO3- secretion)
Loop Diuretics
- Furosemide
Powerful diuretics. Act on thick ascending limb og LOH. Inhibits the Na+K+2CL- co-transporter (competes with Cl- binding). Decreased NaCl reabsorption in thick ascending loop causes decreased osmotic concentration in the medulla thus decreased ADH mediated water absorption.
Binds to plasma proteins so not filtered but secreted directly into the PCT thus effective in renal impairment.
SEs: Hypovolaemia + hypotension, hypokalaemia
Uses: peripheral oedema (chronic heart failure), acute pumonary oedema.
Osmotic diuretic
- Mannitol
Increases the osmolarity of glomerular filtrate thus prevents water reabsorption. Acts mostly where water reabsorption occurs - PCT + descending limb of LOH)
Uses: reducing intracranial pressure + reducing intraocular pressure (glaucoma)
Thiazide Diuretics
- Bendroflumethiazide
- Indapamide
- Hydrochlorothiazide
- Chlortalidone
(BICH)
Weak/moderate diuresis. Acts on the DCT. Inhibits Na+/Cl- co-transporter (competes with Cl- binding). Slower acting bur longer lasting than loop diuretics.
SEs: Hyponatraemia/Hypokalaemia, increased plasma uric acid (gout), ED, Hyperglycaemia
Uses: Peripheral oedema (chronic heart failure), hypertension
Potassium Sparing Diuretics
Subclass: Aldosterone Antagonists
- Spironolactone
- Eplerenone
Weak diuretic alone. Aldosterone antagoniss, binds to and blocks mineralocorticoid (MR) receptor. Prevents synthesis of ENaC and Na+/K+ATPase activity which stops Na+ reabsorption (and water by osmosis) and reduces K+ secretion into the lumen to K+ is retained.
SEs: Hyperkalaemia, gynaecomastia
Uses: Chronic HF, Periph oedema +ascites caused by cirrhosis. Can be used in comination to prevent K+ loss from use of loop/thiazide diuretics.
Potassium Sparing Diuretics
Subclass: ENaC Antagonists
- Amiloride
Weak diuretic alone. ENaC antagonist - blocks ENaC, competes for Na+ binding site thus decreasing luminal permeability to Na+. This causes reduced Potassium secretion into the lumen to potassium is retained
SEs: Hyperkalaemia,
Uses: Chronic heart failure; Peripheral oedema and ascites caused by cirrhosis. Can be used in combination to prevent K+ loss from use of loop/thiazide diuretics
Renin Inhibitor
- Aliskiren
Inhibits the action of Renin thus stopping formation of Angiotensin I so the RAAS system cannot be used to increas BP
Angiotensin-converting Enzyme (ACE) Inhibitor
- Ramipril
Binds to ACE stopping the converstion of Ang I to Ang II so the RAAS system cannot increase BP
SEs: Dry cough (bradykinin build up as not inactivated by ACE), hypotension.
Caution in renal failure - ACE normally constricts efferent arterioles thus ACEI can lead to decreased GFR
Angiotensin-II receptor antagonists
- Losartan
Binds to the angiotensin-II receptor, preventing it from working. RAAS cannot increase BP
Aldosterone Antagonist
- Spironolactone
Antagonist of aldosterone by blocking the mineralocorticoid receptor. Means RAAS cannot increase BP
Thyroid Hormones
- Levothyroxine
- Liothyonine
Mimics thyroid hormone by binding to incracellular alpha & beta thryoid receptors
Alpha-adrenergic blocker
(for urinary retention)
- Doxazosin
Blocks alpha adrenoreceptors of the sympathetic autonomic nervous system, this relaxes smooth muscles around the bladder (internal and external urinary sphincters) allowing micturition.
- Uses: Urinary retention, can be used for benign prostatic hyperplasia*
- Doxazosin - ZO sounds like GO - makes you GO for a wee*
Urinary anti-spasmodic; anticholinergic
(for urinary incontinence)
- Oxybutinin
competitively antagonizes the muscarinic acetylcholine receptor leading to reduction of bladder detrusor activity
B2-Adrenergic Agonists
- Salbutamol (short acting)
- Terbutaline (short acting)
- Salmeterol (long acting)
- Formoterol (long acting)
B2 agonists bind to B2-adrenergic receptors that activate adenylate cyclase. AC increases cAMP levels, activting protein kinase A (PKA). PKA phosphorylates myoin light chain kinase, deactivating it. This causes a reducation in smooth muscle contraction resulting in relaxation of smooth muscle in the airway.
SEs: Tremor, tachycardia, cardiac arrythmia
Anti-cholinergics
- Ipratropium (short acting)
- Tiotropium (long acting)
Targets bronchiolar smooth muscle cells. Blocks M3 muscarinic ACh receptors. Decreases action of PLS, reducing Ca2+ release into the cytoplasm, reducing smooth muscle contraction causing bronchodilation.
SEs: Dry mouth, constipation, urinary retention
Methylxanthines
- Theophylline
- Aminophylline
Targets bronchiolar smooth muscle cells. Blocks phosphodiesterase (PDE). This sustains cAMP levels and promotes muscle relaxation - bronchodilation.
Toxic side effects to must monitor serum - cardic arrythmias + seizures
Leukotriene Antagonists
- Montelukast
- Zafirlukast
Primarily targest mast calls in the lungs. Blocks CysLT leukotriene receptors. This reduces the inflammatory response in early and late phases of asthma
SEs: Abdo pain, headache
Glucocorticoids
- Beclomethasone
- Fluticasone
- Prednisolone
- Hydrocortisone
Targets immune cells of the lungs especially macrophages, T-lymps and eosinophils. Activates the glucocorticoid receptor (GR) which interacts with selected nuclear DNA sequences and influences the expression of g=key genes:
- Repression of pro-inflammatory mediators (TH2 cytokines)
Expression of anti-inflammatory products (B2 adrenoceptors)
SEs: MANY - Moon face, weight gain, osteoporosis, hyperglycaemia
Beta-adrenergic receptor antagonists
(Beta blockers)
- Bisoprolol
- Attenolol (cardioselective B1 antag.)
- Propanolol (B1 & 2 antag.)
Competitive inhibitors of adrenaline and noradrenaline at B-adrenoceptor sites. Inhibit sympathetic stimulation of heart muscle. B1 antagonists are selective for the cardiomyocytes and contractility. Reduce workload on the heart relieving oxygen demand.
Reduces inotropy & chronotropy
SEs: Dizziness, constipation
Calcium Channel Antagonists
(for heart failure and hypertenison)
- Nifedipine
- Amlodipine
Prevent opening of VGCCs. Bind to K-type calcium channels on cardiac and smooth muscle - act on BOTH the heart and vessels. Cause coronary artery dilation. Negative chronotropic effects, negative inotropic effects.
SEs: Ankle swelling, palpitations, interact with B-blockers & grapefruit juice
Nitrate Vasodilators
- Glycerol trinitrate (GTN)
- isosorbide mononitrate (ISMN)
Metabolised to release Nitric Oxide NO which stimulates soluble guanylate cyclase. Increases cGMP in vasc. smooth muscle cells. Drives dephosphorylation of MLC via activation of MLCP causing vascular smooth muscle relaxation.
Can act to dilate arteries AND veins. Venodilation decreases preload. Coronary artery dilarion increases blood and oxygen supply to the myocardium.
SE: Headache
Anti-cholinergic
(for emergency bradycardia treatment)
- Atropine
IV. Binds to and blocks muscarinic M2 Ach receptors in the heart. Inhibits effects of cholinergic vagus nerve transmission (normally chronotropic effects). Accelerates repolarisation rate in cardiac muscle cell, so raises heart rate
Uses: Sinus Bradycardia
Sympathomimetics
- Noradrenaline (alpha)
- Dobutamine (beta)
- Adrenaline (alpha and beta)
Activate the sympathetic NS, stimulatinf cardiac inotropy and chronotropy
Uses: Chronic Heart Failure
ACE inhibitors
- Ramipril
Inhibits conversion of Ang I to Ang II. Reduces vasoconstriction
HMG-CoA Reductase Inhibitors
(statins)
- Atorvastatin
- Simvastatin
Inhibition of malevonate metabolism in cholesterol synthesis pathway
Neprilysin inhibitors
(used with an ARB drug)
- Sacubitril (used with valsartan)
Inhibition of natriuretic peptide breakdown
Antiplatelet Drugs (2)
- Aspirin
Inhibits synthesis of Thromboxane A2 by reversibly inactivating COX1. Less TXA2 can bind to glycoprotein receptiors on another platelet thereby preventing cross-linking of fibrinogen.
- SEs: GI bleeding, gastric ulcers due to decreased prostaglandins E2 and I1*
- Clopidogrel
Binds to and blocks the platelet ADP receptor, causes decreased expression of GPIIb and GPIIIa receptors so decreased platelet aggregation as fibrinogen cannot cross link between platelets.
SEs: GI bleeding and gastric ulcers due to decreased prostaglandins E2 and I2
The cloppy dog has 5 limbs (2+3) GPIIb and GPIIIa
Anticoagulants (4)
- Warfarin
Targest extrinsic pathway which inhibits vitamin K dependent synth of Ca2+ dependent clotting factors 10, 9, 7 and 2. By inhbiting vitamin K carboxylation of the factors it decreases thrombin production.
WKD TimE = _W_arfarin inhibits vitamin _K_, decreasing Thrombin which is Extrinsic pathway.
Vit K is clotting factors 1972 - 10,9,7,2.
- Unfractioned heparins, low molecular weight heparins
Targes intrinsic pathway, activates antithrombin III which inactivates thrombin and Xa. has immediate effect as binds to products already there whereas warfarin must inactivate - Heparin used to bridge treatment for warfarin.
HAITTI - _H_eparins activate _A_nti-thrombin 3, Inactivating Thrombin and TenA -Intrisic pathway
- Dabigatran
Direct inhibition of thrombin - thrombi cannot convert fibrinogen into fibrin and formation of secondary plug is inhibited
A wolf, a hippo and a big dab